Mobilizing the
Human Immune System
to Combat Disease
HiFiBiO Therapeutics is an emerging multinational company that will soon transform patient care.
Home
Mobilizing the
Latest News
Jun 17, 2021
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs Transformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties SAN FRANCISCO, CA and CAMBRIDGE, MA, June 17, 2021 … Continued
Jun 14, 2021
HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS™ Approach in the Clinic
Latest funding led by Mirae Asset Financial Group and joined by B Capital Group, Sherpa, and other new investors together with existing investors such as IDG and Sequoia Capital China CAMBRIDGE, Mass., HONG KONG, HANGZHOU, SHANGHAI, and PARIS, – June 14, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation … Continued
Jun 11, 2021
HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy
HiFiBio Therapeutics announced a publication in Science Advances with its collaborators at Nankai University, ShanghaiTech University, and Jiao Tong University about the development of a high-throughput droplet-based approach to identify novel antibodies with functional readouts beyond simple binding.
Jun 17, 2021
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs Transformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties SAN FRANCISCO, CA and CAMBRIDGE, MA, June 17, 2021 … Continued
Unprecedented Discovery and Development Engine
Drug Discovery and Development Expertise
Back
Drug Discovery and Development Expertise
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
Transformational Single-Cell Platform
Back
Transformational Single-Cell Platform
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
Dynamic and Sustainable Pipeline
Back
Dynamic and Sustainable Pipeline
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
Unique Immune Profiling Translational Focus
Back
Unique Immune Profiling Translational Focus
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
Open-Innovation Strategy
Back
Open-Innovation Strategy
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy
